A new proteomics technology utilizing multidimensional (2D) ion mobility spectrometry separation steps combined with mass spectrometry will be developed to characterize the human plasma proteome. The new instrumentation provides sufficient peak capacity such that a high-throughput analysis of the plasma proteome can be performed without the need for a LC separation step. Thus the measurement can be performed on a timescale that is 30 times faster. The instrumentation will be used to generate Addressable Digital Array Maps (ADAMs) for human plasma analyses. These searchable databases will be utilized in comparative proteomics studies (Phase II) to create a cardiovascular disease ADAM (map). The rapid, high-throughput measurement provided by the 2D IMS instrumentation is groundbreaking in that it is now possible to perform plasma profiling studies on a timescale necessary for population proteomics studies. Such studies are required to identify and score multiple biomarkers to populate the cardiovascular disease ADAM. In the future the map will be used to provide an accurate assessment of health for customers in our personalized medicine business model. The research described in this proposal involves the development of instrumentation required to perform population proteomics studies in a timely fashion. These studies will allow the development of disease biomarker databases that can be used in assessments of disease predisposition for our personalized medicine business model. ? ? ?
